Vertex Pharmaceuticals 作为高增长股票而受到关注，英国批准了新的囊性纤维化治疗方法。 Vertex Pharmaceuticals gains spotlight as a high-growth stock with UK approval for new cystic fibrosis treatment.

人们强调,尽管生物技术部门面临挑战,但甲状腺素制药公司(VRTX)是一个大有前景的高增长存量。 Vertex Pharmaceuticals (VRTX) is highlighted as a promising high-growth stock, despite challenges in the biotech sector. 该公司最近获得英国批准进行细胞纤维化治疗,ALYFTREK,并正在其他国家寻求批准。 The company recently received UK approval for its cystic fibrosis treatment, ALYFTREK, and is pursuing approvals in other countries. Vertex的市场上限为1319.3亿美元,5年收入增长25.83%,吸引了13亿亿富翁的投资。 With a market cap of $131.93 billion and a 5-year revenue growth of 25.83%, Vertex has attracted investments from 13 billionaires. 股票的评级为"中等购买",目标价为506.70美元. The stock is rated "Moderate Buy" with a target price of $506.70.